If you are healthy and between the ages of 30-55 years, you may be eligible to participate in a research study to find out how sugar affects the brain of individuals who carry certain genetic variants.

Are you currently diagnosed with an M. Avium Complex (MAC) infection of your lungs? Have the treatments you received not improved your condition? If so, you may be eligible for a research study to learn if a new medication (Epetraborole) is safe and effective in treating this disease. Monetary compensation will be provided to all participants.

In this study, we want to learn more about the safety and effectiveness of inhaled insulin and continuous glucose monitor (CGM) use compared to usual care for people with type 1 diabetes.

This study is made up of two parts. The first stage is to see how many people with hard-to-treat Type 2 Diabetes may also have high levels of a specific hormone. The second stage is to see if taking a medication to lower that hormone can help diabetes control.

The purpose of this study is to learn more about how an investigational drug (tarlatamab) works in people with extensive-stage small cell lung cancer. In this study, we want to learn more about its safety and tolerability (effects good or bad) when used in combination with one of two other drugs (atezolizumab or durvalumab). We also want to learn more about the combination of the study drug with either atezolizumab or durvalumab and carboplatin and etopopside.

We are looking for people who are between the ages of 30-70 to join a national health study to help us better understand the impact of chronic health conditions on people living with HIV. Both people living with HIV and people without HIV are invited to take part.

Atrasentan is an investigational drug. That means it has not yet been approved by the FDA as a medicine. Researchers want to find out if taking atrasentan along with a drug called an SGLT2 inhibitor is safe and helps people with IgA nephropathy.

Have you been diagnosed with HER2 positive (HER2+) breast cancer and have recently or plan to undergo surgery? If so, you may be able to take part in a research study looking at the safety of giving two drugs trastuzumab and pertuzumab in combination with hormonal therapy after surgery for your breast cancer.

This study is being done to see if the study drug, called BI 764198, may help people with a type of kidney disease called focal segmental glomerulosclerosis (abbreviated FSGS). Researchers are trying to figure out if the study drug can reduce the amount of protein in your urine, also known as "proteinuria".

The purpose of this study is to find out if treatment with the study drug, Bexmarilimab, along with standard of care can help with your type of cancer.